The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results